Day Zero Diagnostics Inc., a Boston, MA-based infectious disease diagnostics company leveraging whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, raised $16M in financing.
This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
The company intends to use the funds to complete development of an improved Blood2Bac™ sample prep protocol, which can capture fungi as well as bacteria, using smaller sample volumes, and at substantially lower cost. The funding will also accelerate development of a prototype for the commercial system, including both the hardware system and the Keynome® family of cloud-based AI algorithms that provides high accuracy organism ID and antimicrobial susceptibility profiling. Using the diagnostic, hospitals will be able to reduce patient length of stay; the overuse of toxic, expensive, and ineffective antibiotics; and most importantly, save lives.
Led by Jong Lee, CEO and co-founder, Day Zero Diagnostics is pioneering a new class of infectious disease diagnostics using whole-genome sequencing and artificial intelligence to revolutionize how the world fights the growing threat of antimicrobial resistance. The company also offers a family of lab services under the epiXact® brand that utilize proprietary technologies to assist healthcare organizations manage infection outbreaks, investigate organisms of interest, and make high-impact decisions.
FinSMEs
22/09/2023